Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
BioSpace
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was "significantly improved" as compared to placebo--the second positive readout for the asset th
pharminent
May 22, 2026 (Last updated: May 22, 2026)
BioSpace
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo–the second positive readout for the asset th
